Press Releases

Sep 09, 2024	Ionis announces pricing of $500.3 million public offering
Sep 09, 2024	Ionis announces proposed public offering of common stock
Aug 28, 2024	Ionis to present at upcoming investor conferences
Aug 01, 2024	Ionis reports second quarter 2024 financial results
Jul 22, 2024	Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 19, 2024	Ionis to hold second quarter 2024 financial results webcast
Jul 18, 2024	Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Jul 08, 2024	Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Jun 25, 2024	Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 18, 2024	Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Jun 17, 2024	Ionis to present at TD Cowen Genetic Medicines & RNA Summit
May 31, 2024	Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 28, 2024	Ionis to hold donidalorsen Phase 3 data webcast
May 23, 2024	New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
May 16, 2024	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024	Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 15, 2024	Ionis to host 2024 virtual Annual Meeting of Stockholders
May 07, 2024	Ionis reports first quarter 2024 financial results
Apr 25, 2024	Ionis Publishes 2023 Corporate Responsibility Report
Apr 23, 2024	Ionis to hold first quarter 2024 financial results webcast
Apr 07, 2024	Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Apr 01, 2024	Ionis to present at upcoming investor conferences
Mar 28, 2024	Ionis to hold olezarsen Phase 3 data webcast
Mar 25, 2024	Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Mar 13, 2024	Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Feb 29, 2024	Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Feb 28, 2024	Ionis to present at upcoming investor conferences
Feb 21, 2024	Ionis reports fourth quarter and full year 2023 financial results
Feb 15, 2024	Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Feb 08, 2024	Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Feb 07, 2024	Ionis to hold fourth quarter and full year 2023 financial results webcast
Jan 22, 2024	Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Jan 08, 2024	Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

Investors & Media

Investor contact

Media contact

Press Releases

Press Releases

Investors & Media

Investor contact

Media contact

Press Releases

Press Releases

Keyword Search